Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells

被引:23
作者
Meng, QH
Xu, JW
Goldberg, ID
Rosen, EM
Greenwald, RA
Fan, SJ
机构
[1] Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Oncol Mol Lab, New Hyde Pk, NY 11040 USA
[2] Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Med, Div Rheumatol, New Hyde Pk, NY 11040 USA
关键词
BRCA1; breast cancer; chemically modified tetracycline; E-cadherin/catenin; invasion; migration;
D O I
10.1023/A:1006732424102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chemically modified tetracyclines (CMTs) are promising anti-cancer agents. In this study, we found that CMT-3 and CMT-8 showed dose-dependent cytotoxicities in MDA-MB-468 human breast cancer cells. Moreover, both CMT-3 and CMT-8 significantly inhibited in vitro cell migration and invasion at non-cytotoxic concentrations. Anti-invasion and migration potentials of the CMTs were associated with an increased expression of E-cadherin/catenins (alpha, beta and gamma -catenin) and tumor suppressor BRCA1. In addition, CMT-3 and CMT-8 abolished or reduced spontaneous and HGF/SF-induced cell invasion and migration in U-373 MG human glioblastoma cells. Our current finding is the first demonstration that CMT-3 and CMT-8 can activate the function of invasion suppressor molecules associated with the suppression of breast cancer cell invasion and migration. Thus, clinical application of CMTs may provide potential benefit for suppression of breast cancer growth, invasion and metastasis.
引用
收藏
页码:139 / 146
页数:8
相关论文
共 66 条
[1]  
Berx G, 1996, ONCOGENE, V13, P1919
[2]   E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers [J].
Berx, G ;
CletonJansen, AM ;
Nollet, F ;
deLeeuw, WJF ;
vandeVijver, MJ ;
Cornelisse, C ;
vanRoy, F .
EMBO JOURNAL, 1995, 14 (24) :6107-6115
[3]  
BOWERS DC, 2000, IN PRESS CANC RES
[4]  
Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123
[5]  
BRACKE ME, 1994, CANCER RES, V54, P4607
[6]  
Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO
[7]  
2-Y
[8]  
Cakir Y, 1999, IN VIVO, V13, P327
[9]  
Charpin C, 1998, AM J CLIN PATHOL, V109, P431
[10]  
Cockett MI, 1998, BIOCHEM SOC SYMP, P295